Imfinzi puts its flag on the Matterhorn
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
ALX plays the conjugate card
Could a new ADC project distract attention away from evorpacept?
ITM hopes to Compete against Lutathera
The German group has posted a PFS win in phase 3, but overall survival was confounded by crossover.
Merck and Sanofi sound the alarm for ILT inhibition
Merck & Co gives up on Agenus, while Sanofi hands BND-22 back to Biond.
Chimerix turns $39m into $935m
The quiet acquisition of dordaviprone prompts a louder takeout by Jazz.
GSK and Hansoh press on despite Pfizer’s exit
A Chinese phase 3 trial of the partners’ B7-H4-targeting ADC has just begun.
T-cell engagement with a difference
In8bio joins Lava in going beyond basic CD3-based T-cell engager MAbs.
